Lexeo Shares Rise On Progress for Heart Disease Treatment
By Nicholas G. Miller
Shares of Lexeo Therapeutics rose in off-hours trading after the company reported progress in discussions with the Food and Drug Administration regarding the accelerated approval pathway for its treatment of Friedreich ataxia cardiomyopathy.
The stock was up 26% to $8.13. As of Monday's close, the stock slipped 24% over the prior 12 months.
The New York company on Monday said the FDA was open to pooling data from Lexeo's ongoing Phase 1/2 studies of the drug, called LX2006. That could shorten the timeline toward submission of a drug application under the accelerated approval pathway, the company said.
Lexeo said its ongoing studies show sustained or deepening improvements for the majority of patients across both cardiac and neurologic measures of Friedreich ataxia.
Friedreich ataxia is a neurodegenerative disease that often leads to cardiomyopathy, a heart condition.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
October 07, 2025 07:12 ET (11:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States